The aim of this review is to describe and summarize the current knowledge regarding the role of incretin hormones in the pathophysiology of obesity and associated cardiometabolic disorders; and their therapeutic potential. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.